LGD-4033 is a selective androgen receptor modulator (SARMS), and a novelnon-steroidal oral SARM that binds to AR with high affinity (Ki of ~1nM) and selectivity. It’s in a class of androgen receptor (AR) ligandsthat is tissue selective, developed to treat muscle wasting associatedwith cancer, acute and chronic illness and age-related muscle loss.LGD-4033 is expected to produce the therapeutic benefits of testosteronewith improved safety, tolerability and patient acceptance due totissue-selective mechanism of action and an oral route of administration.